Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Melanoma and other skin tumours

3381 - PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis

Date

10 Oct 2016

Session

Melanoma and other skin tumours

Presenters

Georgina Long

Citation

Annals of Oncology (2016) 27 (6): 379-400. 10.1093/annonc/mdw379

Authors

G.V. Long1, J. Larkin2, P.A. Ascierto3, F..S. Hodi4, P. Rutkowski5, V. Sileni6, J. Hassel7, C. Lebbe8, A.C. Pavlick9, J. Wagstaff10, D. Schadendorf11, R. Dummer12, D. Hogg13, J.B.A.G. Haanen14, P. Corrie15, C. Hoeller16, C. Horak17, J. Wolchok18, C. Robert19

Author affiliations

  • 1 Medical Oncology, Melanoma Institute Australia, 2065 - Sydney/AU
  • 2 Department Of Medical Oncology, Royal Marsden Hospital, SW3 6JJ - London/GB
  • 3 Melanoma, Cancer Immunotherapy And Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione Pascale, 80131 - Naples/IT
  • 4 Oncology, Dana-Farber Cancer Institute, Boston/US
  • 5 Oncology, MSC Memorial Cancer Centre and Institute Maria Sklodowska-Curie, 02-781 - Warsaw/PL
  • 6 Oncology, Istituto Oncologico Veneto, Padova/IT
  • 7 Oncology, University Hospital Heidelberg, Heidelberg/DE
  • 8 Dermatology, Hôpital St. Louis, 75010 - Paris/FR
  • 9 Department Of Medicine, New York University School of Medicine, New York/US
  • 10 South West Wales Cancer Institute, South West Wales Cancer Institute Singleton Hospital, Sketty, SA2 8QA - Swansea/GB
  • 11 Cancer, University Hospital of Essen, 45147 - Essen/DE
  • 12 Department Of Dermatology, University Hospital Zurich, 8091 - Zurich/CH
  • 13 Department Of Medical Oncology And Hematology, Princess Margaret Hospital, M5G 2M9 - Toronto/CA
  • 14 Department Of Medical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 15 Oncology Centre, Addenbrooke's Hospital University of Cambridge Hospitals, CB2 0QQ - Cambridge/GB
  • 16 Dpt. Of Dermatology And Dermatooncology, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT
  • 17 Clinical Biomarkers, BMS, Princeton/US
  • 18 Ludwig Center, Memorial Sloan Kettering Cancer Center, New York/US
  • 19 Oncology, Gustave Roussy and Paris-Sud University, Villejuif/FR
More

Resources

Abstract 3381

Background

NIVO + IPI and NIVO showed superior clinical activity vs IPI in a phase 3 trial of MEL patients (pts), irrespective of PD-L1 tumor expression. Among pts with high PD-L1 expression (≥5%), median progression-free survival (mPFS) was similar between NIVO + IPI and NIVO, but overall response rate (ORR) was higher with NIVO + IPI. We describe PD-L1 as a biomarker for NIVO + IPI and NIVO efficacy across phase 2 (CheckMate 069) and phase 3 (CheckMate 066 and 067) trials.

Methods

Treatment-naïve pts (N = 832) with MEL received NIVO 1 mg/kg + IPI 3 mg/kg Q3W × 4 or NIVO 3 mg/kg Q2W, followed by NIVO 3 mg/kg Q2W until progression or unacceptable toxicity. Tumor tissue from primary or metastatic sites, obtained at screening, was assessed for PD-L1 expression using a validated Dako immunohistochemistry assay. Minimum pt follow-up was 18 months (mos). Survival data remain immature.

Results

The proportion of pts with PD-L1 expression ≥5% was 26% (92/358) for NIVO + IPI and 29% (139/474) for NIVO. Pt characteristics were similar between PD-L1 subgroups, although fewer pts had LDH > ULN in the PD-L1 ≥5% subgroup. Among pts with PD-L1 expression ≥5%, mPFS of NIVO + IPI was not reached (NR) and was 22.0 mos for NIVO alone (hazard ratio [HR]: 0.99, 95% CI: 0.66─1.46). For pts with low to no PD-L1 (

Conclusions

While pts with ≥5% PD-L1 tumor expression have better efficacy outcomes, those with

Clinical trial identification

NA

Legal entity responsible for the study

Bristol-Myers Squibb

Funding

Bristol-Myers Squibb

Disclosure

G.V. Long: Served as a consultant for GSK, Roche, Novartis, BMS, Amgen, and Merck, and received honoraria from Merck, GSK, Roche. J. Larkin: Institution received research funding from Pfizer, BMS, Novartis, MSD. P.A. Ascierto: Received honoraria from BMS, Roche-Genentech, and GSK, served as a consultant for BMS, Roche-Genentech, MSD, GSK, Ventana, Novartis, and Amgen, and institution received research funding from BMS, Roche-Genentech, and Ventana. F.S. Hodi: Served as a consultant from BMS (non-paid), institution received research funding from BMS, and his institution has a patent pending for immune target. P. Rutkowski: Honoraria from BMS, Roche, Novartis, MSD, and GSK, consulted for BMS, Amgen, Roche, and MSD, participated in speaker's bureau for Pfizer, MSD and Novartis, institution received research funding from BMS, and received travel support from Novartis. V. Sileni: Served as a consultant for Roche, BMS, GSK, and MSD, participated in speaker's bureau for Roche, BMS and GSK, and received travel support from Roche, GSK, MSD, and BMS. J. Hassel: Received honoraria from BMS, GSK, Roche, MSD, and Amgen, served as a consultant for Amgen and GSK, participated in speaker's bureau for BMS, GSK, Roche, MSD, and Amgen, and received travel support from Amgen and BMS. C. Lebbe: Dr. Lebbe served on advisory boards for BMS, MSD, Roche, GSK, Novartis. A.C. Pavlick: Served as a consultant for BMS and Amgen, and participated in speaker's bureau for BMS. J. Wagstaff: Served as a consultant for BMS. D. Schadendorf: Honoraria: Roche, GSK, Amgen, Novartis, BMS, MSD; consultant: Roche, GSK, Amgen, Novartis, BMS, MSD; speakers bureau: Roche, GSK, Amgen, Novartis, BMS, MSD; institutional research funding: MSD, and travel from Roche, GSK, Amgen, Novartis, BMS, MSD. R. Dummer: Paid honoraria from Roche, BMS, GSK, MSD, and Novartis, served as a consultant for Roche, BMS, GSK, MSD, and Novartis, received research funding from Roche, BMS, GSK, MSD, and Novartis. D. Hogg: Served as a consultant for BMS, Roche, Novartis and GSK. J.B.A.G. Haanen: Served as a consultant for MSD, Roche and Pfizer, received research funding from BMS and GSK. P. Corrie: Paid honoraria from Roche, BMS, GSK, and Celgene, served as a consultant for Roche, BMS, Merck, GSK, and Celgene, and received travel support from BMS, Merck and Roche. C. Hoeller: Paid honoraria from BMS, MSD, Roche, Novartis, Amgen and GSK, served as a consultant for BMS, MSD, Roche and Amgen, received research funding from BMS, MSD, Roche, Novartis, and GSK. C. Horak: Employed by BMS and owns stock in BMS. J. Wolchok: Honoraria: EMD Serono, Janssen Oncology; consultant: BMS, Merck, MedImmune, Ziopharm, Polynoma, Polaris, Jounce, GSK; institutional research funding: BMS, MedImmune, GSK, Merck; co-investor in patent for DNA vaccines of cancer in animals; travel: BMS. C. Robert: Paid honoraria from BMS, Merck, GSK, Roche, Novartis and Amgen, served as a consultant for BMS, Merck, GSK, Roche, Novartis, and Amgen.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings